Clinical effect of neutralizing antibodies to interferon beta that persist long after cessation of therapy for multiple sclerosis

Archives of Neurology

Volumn 67, Issue 4, 2010, Pages 402-407

  Van Der Voort, Laura F ^a   Gilli, Francesca ^b   Bertolotto, Antonio ^b   Knol, Dirk L ^a   Uitdehaag, Bernard M J ^a   Polman, Chris H ^a   Killestein, Joep ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ASO San Luigi Gonzaga   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON ANTIBODY; INTERFERON BETA SERINE; MITOXANTRONE; NATALIZUMAB; NEUTRALIZING ANTIBODY;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISABILITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; HUMAN; MULTIPLE SCLEROSIS; NETHERLANDS; PRIORITY JOURNAL; RATING SCALE; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; WALKING DIFFICULTY;

ADULT; ANTIBODIES, NEUTRALIZING; ANTINEOPLASTIC AGENTS; CENTRAL NERVOUS SYSTEM; DISABILITY EVALUATION; DISEASE PROGRESSION; DRUG RESISTANCE; FEMALE; HUMANS; IATROGENIC DISEASE; IMMUNE SYSTEM; INTERFERON-BETA; MALE; MITOXANTRONE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RECURRENCE; RETROSPECTIVE STUDIES; TIME;

EID: 77950876430     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2010.21     Document Type: Article

References (26)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med. 2000;343(13):938-952.
2. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis I: clinical results of a multicenter, randomized, doubleblind, placebo-controlled trial. Neurology. 1993;43(4):655-661.
3. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet. 1998;352(9139):1498-1504.
4. Jacobs LD, Cookfair DL, Rudick RA, et al; The Multiple Sclerosis Collaborative Research Group (MSCRG). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol. 1996;39(3):285-294.
5. Ross C, Clemmesen KM, Svenson M, et al; Danish Multiple Sclerosis Study Group. Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Ann Neurol. 2000;48(5):706-712.
6. Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov. 2002;1(6):457-462.
7. Shinohara K, Mitani N, Miyazaki M, et al. Pure red-cell aplasia caused by the antibody to recombinant erythropoietin, epoetin-beta, in a Japanese patient with chronic renal failure. Am J Hematol. 2005;78(1):15-20. (Pubitemid 40023741)
8. Bertolotto A, Gilli F, Sala A, et al. Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients. Neurology. 2003;60(4):634-639. (Pubitemid 36246082)
9. Phillips JT, O'Connor PW, Havrdova E, et al; AFFIRM Investigators. Infusion-related hypersensitivity reactions during natalizumab treatment. Neurology. 2006;67(9):1717-1718.
10. Goodin DS, Frohman EM, Hurwitz B, et al. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2007;68(13):977-984. (Pubitemid 46569129)
11. Kappos L, Clanet M, Sandberg-Wollheim M, et al; European Interferon Beta-1a IM Dose-Comparison Study Investigators. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology. 2005;65(1):40-47.
12. Sorensen PS. Neutralising antibodies to interferon-beta: measurement, clinical relevance, and management. J Neurol. 2006;253(suppl 6):vi16-vi22.
13. van der Voort LF, Kok A, Visser A, et al. Interferon-beta bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice. Mult Scler. 2009;15(2):212-218.
14. Petersen B, Bendtzen K, Koch-Henriksen N, Ravnborg M, Ross C, Sorensen PS; Danish Multiple Sclerosis Group. Persistence of neutralizing antibodies after discontinuation of IFNbeta therapy in patients with relapsing-remitting multiple sclerosis. Mult Scler. 2006;12(3):247-252. (Pubitemid 43832494)
15. Reske D, Walser A, Haupt WF, Petereit HF. Long-term persisting interferon beta-1b neutralizing antibodies after discontinuation of treatment. Acta Neurol Scand. 2004;109(1):66-70. (Pubitemid 38161129)
16. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444-1452.
17. Grossberg SE, Kawade Y, Kohase M, Klein JP. The neutralization of interferons by antibody II: neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit. J Interferon Cytokine Res. 2001;21(9):743-755. (Pubitemid 32955704)
18. Kawade Y, Finter N, Grossberg SE. Neutralization of the biological activity of cytokines and other protein effectors by antibody: theoretical formulation of antibody titration curves in relation to antibody affinity. J Immunol Methods. 2003;278(1-2):127-144. (Pubitemid 37281197)
19. Sominanda A, Hillert J, Fogdell-Hahn A. In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependent. J Neurol Neurosurg Psychiatry. 2008;79(1):57-62.
20. Deisenhammer F, Schellekens H, Bertolotto A. Measurement of neutralizing antibodies to interferon beta in patients with multiple sclerosis. J Neurol. 2004;251(suppl 2):II31-II39.
21. Hartung HP, Polman C, Bertolotto A, et al. Neutralising antibodies to interferon beta in multiple sclerosis: expert panel report. J Neurol. 2007;254(7):827-837.
22. Sorensen PS, Koch-Henriksen N, Ross C, Clemmesen KM, Bendtzen K; Danish Multiple Sclerosis Study Group. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology. 2005;65(1):33-39.
23. Manz RA, Arce S, Cassese G, Hauser AE, Hiepe F, Radbruch A. Humoral immunity and long-lived plasma cells. Curr Opin Immunol. 2002;14(4):517-521.
24. Maruyama M, Lam KP, Rajewsky K. Memory B-cell persistence is independent of persisting immunizing antigen. Nature. 2000;407(6804):636-642.
25. Giovannoni G. Strategies to treat and prevent the development of neutralizing anti-interferon-beta antibodies. Neurology. 2003;61(9)(suppl 5):S13-S17. (Pubitemid 37386113)
26. Hesse D, Frederiksen JL, Koch-Henriksen N, et al. Methylprednisolone does not restore biological response in multiple sclerosis patients with neutralizing antibodies against interferon-beta. Eur J Neurol. 2009;16(1):43-47.